Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 16 ... use has increased for two consecutive quarters from 34.8 percent to 36.7 percent of the taxane market. On a rolling 12-month basis, the ABRAXANE share of the total MBC...
2009 OCT 19 ... to crossing the blood-brain barrier. ANG1005 is a novel, next-generation taxane derivative, targeting the LRP pathway to cross the blood-brain barrier and reach ...
2009 OCT 19 ... can be potentiated by taxanes and other chemotherapeutic agents, and that the ReoT3D-taxane combination most effectively achieves synergy through accelerated apoptosis triggered by ...
2009 NOV 1 ... method developed as an alternative to harvesting tree bark or plantations as a taxane source. The patent will broadly cover methods for producing commercial ...
2009 NOV 2 ... models refractory/resistant to taxanes, and have demonstrated clinical activity in taxane pre-treated/resistant metastatic breast cancer (MBC) patients. The current phase I ...
2009 NOV 23 ... loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. Ganite and Genasense are ...
2009 NOV 9 ... two and a maximum of five prior chemotherapy regimens, including an anthracycline and a taxane. The patients were treated either with eribulin (administered intravenously ...
2009 OCT 12 ... as well as significant preclinical work demonstrating synergy in combination with taxane or platinum-based drugs. Interim results of the U.K. Phase 1/2 trial reported in March ...
2009 NOV 1 ... assets of NPI, which include intellectual property and patents for the production of taxane API's, a fully-staffed cGMP manufacturing facility in Delta, BC, Canada, and an API ...
2009 OCT 19 ... experienced a partial or stable response on this therapy, 72% of whom were previously taxane-refractory," wrote A.J. Chien and colleagues, University of California. ...
2009 NOV 2 ... bladder cancer to improve survival outcomes. A randomized trial of larotaxel (a novel taxane) and cisplatin vs cisplatin and gemcitabine in frontline therapy of metastatic ...
2009 NOV 23 ... a progression-free survival of 19 months. This outpatient regimen of IV and IP platinum-taxane chemotherapy is well tolerated with acceptable toxicity. Importantly, most patients were ...
2009 NOV 9 ... 6 months) and survival in patients with epithelial ovarian cancer (EOC) who received taxane- and platinum-based chemotherapy after surgery. Between December 2005 and August 2007, ...
2009 NOV 23 ... salvage treatment for Japanese metastatic breast cancer patients after anthracycline and taxane treatment,' is the subject of a report. "This Phase II study was conducted to evaluate ...
2009 OCT 12 ... published in the journal Anticancer Research, "In this study, the effect of novel taxane SB-T-1216 and paclitaxel on sensitive MDA-MB-435 and resistant NCI/ADR-RES human breast ...
2009 NOV 2 ... disease." "Surgery is then usually followed by six cycles of platinum-taxane chemotherapy. Older patients often have comorbidities which limit treatment choice and ...
2009 NOV 2 ... Ruhstaller and colleagues. The researchers concluded: "This neoadjuvant, taxane-containing regimen was efficacious and feasible in patients with locally advanced ...
2009 NOV 1 ... groups. The median age of the women was 50. All received neoadjuvant anthracycline- and taxane-based chemotherapy; receiving similar class of therapy was an important component in the ...
Subject: University of Texas M. D. Anderson Cancer Center
